Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | FURIN | P09958 | 10/20 | 0.49 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
| ▸ | GNPAT | O15228 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30565184 | 0.92 | SIRT6 (0.59) | SIRT6SIRT1SIRT5GNPAT | |
| SCHEMBL29723634 | 0.92 | SIRT6 (0.59) | SIRT6SIRT1SIRT5GNPAT | |
| SCHEMBL29727369 | 0.90 | FURIN (0.45) | SIRT6SIRT1FURINPCSK6PRSS1 | |
| SCHEMBL30317673 | 0.89 | SIRT5 (0.52) | FURINSIRT5GNPAT | |
| SCHEMBL30317615 | 0.89 | SIRT5 (0.46) | SIRT6SIRT1FURINPCSK6SIRT5 | |
| SCHEMBL18688864 | 0.88 | GNPAT (0.45) | SIRT6SIRT1FURINSIRT5GNPAT | |
| SCHEMBL28574926 | 0.88 | GNPAT (0.45) | SIRT6SIRT1FURINSIRT5GNPAT | |
| SCHEMBL30317597 | 0.88 | GNPAT (0.59) | FURINSIRT5GNPAT | |
| SCHEMBL29371278 | 0.88 | GNAI3 (0.44) | FURINPRSS1 | |
| SCHEMBL20435368 | 0.86 | SIRT6 (0.55) | SIRT6SIRT1FURINPCSK6SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262314-A1 | MULTIFUNCTIONAL ANTIBODIES | SYNAFFIX B.V. (NL) | 2025-08-21 | — | — | US | claimed |
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | US | claimed |
| WO-2025120085-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | WO | claimed |
| WO-2025103474-A1 | DOUBLE-TOXIN ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 成都康弘生物科技有限公司 | 2025-05-22 | — | — | WO | claimed |
| CN-120019819-A | Double toxin antibody drug conjugate and application thereof | 成都康弘生物科技有限公司 | 2025-05-20 | — | — | CN | claimed |
| US-20250154270-A1 | ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF | PFIZER INC. (US) | 2025-05-15 | — | — | US | claimed |
| US-20250067753-A1 | Protein array-based in vitro transglutaminase assay platform for epitope mapping and immunogen design | LIU CHEN (US) | 2025-02-27 | — | — | US | claimed |
| CN-119424672-A | Antibody drug conjugate and application thereof | 成都康弘生物科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| EP-4288108-A1 | MULTIFUNCTIONAL ANTIBODIES | Synaffix B.V. (NL) | 2023-12-13 | — | — | EP | claimed |
| US-20230357417-A1 | ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF | PFIZER INC. (US) | 2023-11-09 | — | — | US | claimed |
| US-20230330245-A1 | ANTIBODY-EXATECAN CONJUGATES | SYNAFFIX B.V. (NL) | 2023-10-19 | — | — | US | claimed |
| EP-4213885-A1 | ANTIBODY-EXATECAN CONJUGATES | Synaffix B.V. (NL) | 2023-07-26 | — | — | EP | claimed |
| US-11613581-B2 | Antibodies and antibody-drug conjugates specific for CD123 and uses thereof | PFIZER, INC. (US) | 2023-03-28 | — | — | US | claimed |
| US-11602525-B2 | Antibody-drug conjugates with high drug loading | RINAT NEUROSCIENCE CORP. (US) | 2023-03-14 | — | — | US | claimed |
| WO-2023021335-A2 | PROTEIN ARRAY-BASED IN VITRO TRANSGLUTAMINASE ASSAY PLATFORM FOR EPITOPE MAPPING AND IMMUNOGEN DESIGN | LIU CHEN (US) | 2023-02-23 | — | — | WO | claimed |
| WO-2022167689-A9 | MULTIFUNCTIONAL ANTIBODIES | SYNAFFIX B.V. (NL) | 2022-11-10 | — | — | WO | claimed |
| WO-2022167689-A1 | MULTIFUNCTIONAL ANTIBODIES | SYNAFFIX B.V. (NL) | 2022-08-11 | — | — | WO | claimed |
| WO-2022058395-A1 | ANTIBODY-EXATECAN CONJUGATES | SYNAFFIX B.V. (NL) | 2022-03-24 | — | — | WO | claimed |
| US-20260139067-A1 | CDCP1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2022049211-A1 | METHODS FOR THE PREPARATION OF BIOCONJUGATES | SYNAFFIX B.V. (NL) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139067-A1 | CDCP1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | DOCK2, CD2BP2, CDV3 | SIRT6 4426/4885SIRT1 4743/4885FURIN 3771/4885 |
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | BCR, TBCD, TBC1D5 | SIRT6 2231/4885SIRT1 3210/4885FURIN 1487/4885 |
| US-20230357417-A1 | ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF | CD2, CD22, ENTPD3 | SIRT6 2423/4885SIRT1 3666/4885FURIN 3828/4885 |
| US-20250154270-A1 | ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF | CD2, CD22, ENTPD3 | SIRT6 2423/4885SIRT1 3666/4885FURIN 3828/4885 |
| US-11602525-B2 | Antibody-drug conjugates with high drug loading | GATD3, GLUL, SLC7A11 | SIRT6 998/4885SIRT1 2337/4885FURIN 1601/4885 |
| US-20230330245-A1 | ANTIBODY-EXATECAN CONJUGATES | ERBB3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL23R | SIRT6 2953/4885SIRT1 2419/4885FURIN 944/4885 |
| US-11613581-B2 | Antibodies and antibody-drug conjugates specific for CD123 and uses thereof | CD2, CD22, ENTPD3 | SIRT6 2423/4885SIRT1 3666/4885FURIN 3828/4885 |
| US-20250262314-A1 | MULTIFUNCTIONAL ANTIBODIES | C1S, APOL1, BTN3A1 | SIRT6 4675/4885SIRT1 4250/4885FURIN 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.